PZKKN-94 is a dual serotonin 5-HT<sub>1B</sub> receptor agonist and serotonin 5-HT<sub>6</sub> receptor antagonist which is under investigation for the potential treatment of Parkinson's disease. Its values were 39nM () and 88.1% () at the serotonin 5-HT<sub>1B</sub> receptor and 7.7nM (K<sub>B</sub>) at the serotonin 5-HT<sub>6</sub> receptor. The drug showed selectivity for these receptors over 43other targets. It shows favorable drug-like properties. In rodents, PZKKN-94 shows antiparkinsonian-like, pro-cognitive, and antidepressant-like effects. PZKNN-94 was first described in the scientific literature by Paweà  Zajdel and colleagues in 2025.